SCHEMBL2826952

SCHEMBL2826952

Cc1ccccc1-c1nccc(C(=O)c2ccc(F)cc2F)c1NC(=O)C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 5/20 0.44
▸ ABL1 P00519 2/20 0.42
▸ LMNA P02545 1/20 0.39
▸ MAPK13 O15264 2/20 0.37
▸ MAPK12 P53778 2/20 0.37
▸ MAPK11 Q15759 2/20 0.37
▸ DHODH Q02127 1/20 0.37
▸ TDP1 Q9NUW8 2/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ BDKRB1 P46663 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2079338 0.89 MAPK14 (0.43) MAPK14LMNAMAPK13MAPK12MAPK11
SCHEMBL4078010 0.85 MAPK14 (0.40) MAPK14ABL1LMNAMAPK13MAPK12
SCHEMBL2076784 0.82 MAPK14 (0.42) MAPK14LMNAMAPK13MAPK12MAPK11
SCHEMBL1642475 0.80 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11
SCHEMBL4072017 0.77 ABL1 (0.36) MAPK14ABL1MAPK13MAPK12MAPK11
SCHEMBL2825730 0.77 MAPK13 (0.38) MAPK14ABL1LMNAMAPK13MAPK12
SCHEMBL13353942 0.76 ABL1 (0.35) MAPK14ABL1LMNAMAPK13MAPK12
SCHEMBL2829217 0.76 EGFR (0.39) MAPK14ABL1LMNAMAPK13MAPK12
SCHEMBL2079067 0.74 ABL1 (0.34) MAPK14ABL1MAPK13MAPK12MAPK11
SCHEMBL1643097 0.71 TSHR (0.41) MAPK14ABL1TDP1L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8334294-B2 4,8-diphenyl-polyazanaphthalene derivatives ALMIRALL, S.A. (ES) 2012-12-18 — — US disclosed
EP-2146988-B1 NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES ALMIRALL SA (ES) 2012-08-15 — — EP disclosed
US-20100130517-A1 NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES ALMIRALL, S.A. (ES) 2010-05-27 — — US disclosed
EP-2146988-A1 NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES Almirall, S.A. (ES) 2010-01-27 — — EP disclosed
WO-2008131922-A1 NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES ALMIRALL, S.A. (ES) 2008-11-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130517-A1 NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES MAPK8, MAPK4, MAP3K8 MAPK14 17/4885ABL1 195/4885LMNA 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback